Overview

Duloxetine for Multiple Sclerosis Pain

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple Sclerosis.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Duloxetine Hydrochloride